Advisors Capital Management LLC Acquires 2,095 Shares of Amgen Inc. $AMGN

Advisors Capital Management LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 3.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,861 shares of the medical research company’s stock after purchasing an additional 2,095 shares during the quarter. Advisors Capital Management LLC’s holdings in Amgen were worth $19,997,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC boosted its holdings in Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after acquiring an additional 3,619 shares during the last quarter. Atlantic Union Bankshares Corp raised its holdings in shares of Amgen by 165.0% in the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after purchasing an additional 6,627 shares during the last quarter. Davis Capital Management bought a new position in shares of Amgen during the third quarter valued at about $1,841,000. D.A. Davidson & CO. boosted its holdings in Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after purchasing an additional 6,222 shares during the last quarter. Finally, Global Wealth Management Investment Advisory Inc. grew its position in Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after purchasing an additional 4,699 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on AMGN shares. Daiwa Securities Group raised their target price on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Guggenheim lifted their price objective on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. DZ Bank boosted their target price on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Wells Fargo & Company raised their target price on Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada boosted their target price on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $354.04.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.76% of the stock is owned by company insiders.

Amgen Stock Performance

Amgen stock opened at $373.36 on Wednesday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $385.12. The stock’s 50 day simple moving average is $339.62 and its two-hundred day simple moving average is $314.83. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a market cap of $201.05 billion, a price-to-earnings ratio of 26.24, a PEG ratio of 3.78 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.